Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870193 | 0.88 | HSD11B1 (0.74) | HSD11B1ALDH1A1CHRM1 | |
| SCHEMBL22869508 | 0.88 | HSD11B1 (0.74) | HSD11B1ALDH1A1CHRM1 | |
| SCHEMBL30870358 | 0.88 | HSD11B1 (0.66) | HSD11B1ALDH1A1CHRM1 | |
| SCHEMBL22869654 | 0.88 | HSD11B1 (0.66) | HSD11B1ALDH1A1CHRM1 | |
| SCHEMBL22869573 | 0.86 | HSD11B1 (0.64) | HSD11B1ALDH1A1LMNAOPRM1OPRD1 | |
| SCHEMBL30870573 | 0.86 | HSD11B1 (0.64) | HSD11B1ALDH1A1LMNAOPRM1OPRD1 | |
| SCHEMBL28905074 | 0.86 | HSD11B1 (0.64) | HSD11B1ALDH1A1LMNAOPRM1OPRD1 | |
| SCHEMBL22869849 | 0.85 | HSD11B1 (0.65) | HSD11B1ALDH1A1CHRM1 | |
| SCHEMBL22869513 | 0.85 | HSD11B1 (0.63) | HSD11B1ALDH1A1CHRM1HTTOPRM1 | |
| SCHEMBL30870262 | 0.85 | HSD11B1 (0.65) | HSD11B1ALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074511-A | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2020-12-11 | — | — | CN | claimed |
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-01-07 | — | — | US | disclosed |
| CN-112074511-A | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2020-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP4X1, CYP11B2 | HSD11B1 256/4885ALDH1A1 330/4885CHRM1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.